Halia Therapeutics and Biolexis Therapeutics Announce Key Breakthrough in Neuroinflammation Research
Thursday, August 01, 2024
Halia Therapeutics, a biopharmaceutical company focused on novel small molecule therapies for inflammation, and Biolexis Therapeutics, known for its AI-driven drug discovery, have announced a significant advancement in their collaboration. Together, they have discovered a new brain-penetrant small molecule candidate that targets NLRP3-driven neuroinflammation using Biolexis' MolecuLern™ AI technology. This discovery marks an important step forward in developing treatments for neuroinflammatory disorders, including Parkinson’s disease and other neurodegenerative conditions.
Halia Therapeutics and Co-Founder and Chairman of Biolexis Therapeutics, commented, “We are extremely pleased with the outcomes of our collaboration with Biolexis Therapeutics. Their innovative AI technology has enabled us to pinpoint a highly promising clinical candidate that could revolutionize the treatment landscape for neuroinflammatory diseases. This partnership underscores the potential of combining advanced AI tools with our neuroinflammation expertise.”
Biolexis Therapeutics, added, “Partnering with Halia Therapeutics has been an excellent showcase of our MolecuLern approach. We are excited about the prospects of this new clinical candidate and look forward to its progress through development. This effort highlights the effectiveness of our AI-driven approach in accelerating the discovery of groundbreaking therapeutics.”
Biolexis Therapeutics’ MolecuLern AI technology has been key in identifying promising therapeutic candidates with favorable efficacy and safety profiles for challenging protein targets. The newly identified candidate will move into preclinical studies, aiming to provide a novel treatment for neuroinflammatory conditions like Parkinson’s disease. These conditions involve chronic brain inflammation and progressive neuronal damage, presenting significant clinical hurdles. The new therapy is designed to address these challenges by targeting NLRP3-driven neuroinflammation.
Source: haliatx.com
